|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-17
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels <50? mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600? mg/day or placebo in addition to their existing treatments. Brachial flow-mediated dilatation (FMD) measured by B-mode ultrasound represents endothelial function and is a validated marker for early atherosclerosis and cardiovascular disease risk.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
pubmed-author:BurgessTracyT,
pubmed-author:DeanfieldJohnJ,
pubmed-author:DuivenvoordenRaphaëlR,
pubmed-author:JukemaJ WouterJW,
pubmed-author:KallendDavidD,
pubmed-author:KaskiJuan-CarlosJC,
pubmed-author:KasteleinJohn J PJJ,
pubmed-author:LüscherThomas FTF,
pubmed-author:LehnertValerieV,
pubmed-author:MünzelThomasT,
pubmed-author:TaddeiStefanoS,
pubmed-author:de GrootEricE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
141-50
|
|
pubmed:dateRevised |
2011-8-25
|
|
pubmed:meshHeading |
pubmed-meshheading:21128879-Adolescent,
pubmed-meshheading:21128879-Adult,
pubmed-meshheading:21128879-Aged,
pubmed-meshheading:21128879-Algorithms,
pubmed-meshheading:21128879-Anticholesteremic Agents,
pubmed-meshheading:21128879-Brachial Artery,
pubmed-meshheading:21128879-Coronary Disease,
pubmed-meshheading:21128879-Double-Blind Method,
pubmed-meshheading:21128879-Endothelium, Vascular,
pubmed-meshheading:21128879-Female,
pubmed-meshheading:21128879-Humans,
pubmed-meshheading:21128879-Male,
pubmed-meshheading:21128879-Middle Aged,
pubmed-meshheading:21128879-Models, Biological,
pubmed-meshheading:21128879-Placebos,
pubmed-meshheading:21128879-Rationalization,
pubmed-meshheading:21128879-Regional Blood Flow,
pubmed-meshheading:21128879-Research Design,
pubmed-meshheading:21128879-Sulfhydryl Compounds,
pubmed-meshheading:21128879-Treatment Outcome,
pubmed-meshheading:21128879-Vasodilation,
pubmed-meshheading:21128879-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
|
|
pubmed:affiliation |
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. j.j.kastelein@amc.uva.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
